Julian Kirchner1,2, Joseph A O'Donoghue3, Anton S Becker1, Gary A Ulaner4,5,6. 1. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Diagnostic and Interventional Radiology, University Dusseldorf, Medical Faculty, Dusseldorf, Germany. 3. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Gary.Ulaner@hoag.org. 5. Department of Radiology, Weill Cornell Medical College, New York, NY, USA. Gary.Ulaner@hoag.org. 6. Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, CA, USA. Gary.Ulaner@hoag.org.
Abstract
PURPOSE: The aim of this study was to evaluate the use of a Bayesian penalized likelihood reconstruction algorithm (Q.Clear) for 89Zr-immunoPET image reconstruction and its potential to improve image quality and reduce the administered activity of 89Zr-immunoPET tracers. METHODS: Eight 89Zr-immunoPET whole-body PET/CT scans from three 89Zr-immunoPET clinical trials were selected for analysis. On average, patients were imaged 6.3 days (range 5.0-8.0 days) after administration of 69 MBq (range 65-76 MBq) of [89Zr]Zr-DFO-daratumumab, [89Zr]Zr-DFO-pertuzumab, or [89Zr]Zr-DFO-trastuzumab. List-mode PET data was retrospectively reconstructed using Q.Clear with incremental β-values from 150 to 7200, as well as standard ordered-subset expectation maximization (OSEM) reconstruction (2-iterations, 16-subsets, a 6.4-mm Gaussian transaxial filter, "heavy" z-axis filtering and all manufacturers' corrections active). Reduced activities were simulated by discarding 50% and 75% of original counts in each list mode stream. All reconstructed PET images were scored for image quality and lesion detectability using a 5-point scale. SUVmax for normal liver and sites of disease and liver signal-to-noise ratio were measured. RESULTS: Q.Clear reconstructions with β = 3600 provided the highest scores for image quality. Images reconstructed with β-values of 3600 or 5200 using only 50% or 25% of the original counts provided comparable or better image quality scores than standard OSEM reconstruction images using 100% of counts. CONCLUSION: The Bayesian penalized likelihood reconstruction algorithm Q.Clear improved the quality of 89Zr-immunoPET images. This could be used in future studies to improve image quality and/or decrease the administered activity of 89Zr-immunoPET tracers.
PURPOSE: The aim of this study was to evaluate the use of a Bayesian penalized likelihood reconstruction algorithm (Q.Clear) for 89Zr-immunoPET image reconstruction and its potential to improve image quality and reduce the administered activity of 89Zr-immunoPET tracers. METHODS: Eight 89Zr-immunoPET whole-body PET/CT scans from three 89Zr-immunoPET clinical trials were selected for analysis. On average, patients were imaged 6.3 days (range 5.0-8.0 days) after administration of 69 MBq (range 65-76 MBq) of [89Zr]Zr-DFO-daratumumab, [89Zr]Zr-DFO-pertuzumab, or [89Zr]Zr-DFO-trastuzumab. List-mode PET data was retrospectively reconstructed using Q.Clear with incremental β-values from 150 to 7200, as well as standard ordered-subset expectation maximization (OSEM) reconstruction (2-iterations, 16-subsets, a 6.4-mm Gaussian transaxial filter, "heavy" z-axis filtering and all manufacturers' corrections active). Reduced activities were simulated by discarding 50% and 75% of original counts in each list mode stream. All reconstructed PET images were scored for image quality and lesion detectability using a 5-point scale. SUVmax for normal liver and sites of disease and liver signal-to-noise ratio were measured. RESULTS: Q.Clear reconstructions with β = 3600 provided the highest scores for image quality. Images reconstructed with β-values of 3600 or 5200 using only 50% or 25% of the original counts provided comparable or better image quality scores than standard OSEM reconstruction images using 100% of counts. CONCLUSION: The Bayesian penalized likelihood reconstruction algorithm Q.Clear improved the quality of 89Zr-immunoPET images. This could be used in future studies to improve image quality and/or decrease the administered activity of 89Zr-immunoPET tracers.
Authors: Neeta Pandit-Taskar; Joseph A O'Donoghue; Volkan Beylergil; Serge Lyashchenko; Shutian Ruan; Stephen B Solomon; Jeremy C Durack; Jorge A Carrasquillo; Robert A Lefkowitz; Mithat Gonen; Jason S Lewis; Jason P Holland; Sarah M Cheal; Victor E Reuter; Joseph R Osborne; Massimo F Loda; Peter M Smith-Jones; Wolfgang A Weber; Neil H Bander; Howard I Scher; Michael J Morris; Steven M Larson Journal: Eur J Nucl Med Mol Imaging Date: 2014-08-21 Impact factor: 9.236
Authors: Gary A Ulaner; David M Hyman; Serge K Lyashchenko; Jason S Lewis; Jorge A Carrasquillo Journal: Clin Nucl Med Date: 2017-12 Impact factor: 7.794
Authors: Gary A Ulaner; David M Hyman; Dara S Ross; Adriana Corben; Sarat Chandarlapaty; Shari Goldfarb; Heather McArthur; Joseph P Erinjeri; Stephen B Solomon; Hartmuth Kolb; Serge K Lyashchenko; Jason S Lewis; Jorge A Carrasquillo Journal: J Nucl Med Date: 2016-05-05 Impact factor: 10.057
Authors: Gary A Ulaner; Nicholas B Sobol; Joseph A O'Donoghue; Assen S Kirov; Christopher C Riedl; Ryan Min; Eric Smith; Lukas M Carter; Serge K Lyashchenko; Jason S Lewis; C Ola Landgren Journal: Radiology Date: 2020-04-07 Impact factor: 11.105
Authors: Eugene J Teoh; Daniel R McGowan; Kevin M Bradley; Elizabeth Belcher; Edward Black; Fergus V Gleeson Journal: Eur Radiol Date: 2015-05-20 Impact factor: 5.315
Authors: Sarah R Verhoeff; Suzanne C van Es; Eline Boon; Erik van Helden; Lindsay Angus; Sjoerd G Elias; Sjoukje F Oosting; Erik H Aarntzen; Adrienne H Brouwers; Thomas C Kwee; Sandra Heskamp; Otto S Hoekstra; Henk Verheul; Astrid A M van der Veldt; Elisabeth G E de Vries; Otto C Boerman; Winette T A van der Graaf; Wim J G Oyen; Carla M L van Herpen Journal: Eur J Nucl Med Mol Imaging Date: 2019-06-06 Impact factor: 9.236
Authors: Eugene J Teoh; Daniel R McGowan; Ruth E Macpherson; Kevin M Bradley; Fergus V Gleeson Journal: J Nucl Med Date: 2015-07-09 Impact factor: 10.057
Authors: Julian M M Rogasch; Frank Hofheinz; Lutz van Heek; Conrad-Amadeus Voltin; Ronald Boellaard; Carsten Kobe Journal: Diagnostics (Basel) Date: 2022-02-10
Authors: Nicolas Aide; Charline Lasnon; Adam Kesner; Craig S Levin; Irene Buvat; Andrei Iagaru; Ken Hermann; Ramsey D Badawi; Simon R Cherry; Kevin M Bradley; Daniel R McGowan Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-03 Impact factor: 9.236